Calderasib + MK-3475A for Non-Small Cell Lung Cancer

(KANDLELIT-013 Trial)

This trial tests a new treatment combination for a specific type of non-small cell lung cancer with the KRAS G12C genetic mutation. The goal is to determine if adding calderasib, a potential new drug, to the existing treatment of MK-3475A helps patients remain cancer-free longer after surgery. Participants will receive either the new combination or a placebo (inactive substance) along with MK-3475A. This trial may suit individuals who have had this type of lung cancer surgically removed and show no current signs of cancer based on recent scans. As a Phase 3 trial, it represents the final step before FDA approval, offering patients a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research shows that calderasib, when combined with pembrolizumab, is generally well-tolerated by patients. Previous studies have found that this combination improves outcomes for people with advanced non-small cell lung cancer (NSCLC). Although some serious side effects have been reported, they are rare. In one study, many patients experienced their cancer shrinking or stopping its growth with this treatment.

Calderasib + MK-3475A is unique because it combines two powerful approaches to tackle non-small cell lung cancer. Unlike standard treatments like chemotherapy and targeted therapies, Calderasib is a novel compound that potentially disrupts cancer cell growth by targeting specific pathways. Meanwhile, MK-3475A, also known as pembrolizumab, is an immunotherapy that helps the immune system recognize and attack cancer cells more effectively. Researchers are excited because this combination might provide a more robust and comprehensive attack on cancer cells, potentially leading to better outcomes for patients.

In this trial, participants will receive either Calderasib combined with MK-3475A or a placebo combined with MK-3475A. Studies have shown that Calderasib, when used with pembrolizumab (the active component of MK-3475A), leads to strong responses in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC). In some trials, this combination helped shrink tumors in up to 72% of patients. Calderasib targets the KRAS G12C mutation, common in lung cancer, making it a promising treatment option. Research indicates that this combination can slow cancer growth and extend patient survival. These findings suggest that Calderasib plus pembrolizumab could be effective for patients with this specific type of lung cancer.¹²³⁴⁶